Gutenberg Test Page - Lustgarten Foundation: Pancreatic Cancer Research

Gutenberg Test Page

Juneteenth Webinar:
Meet Dr. Posey

Pancreatic cancer is a uniquely challenging disease, requiring bold and innovative science. We know these challenges are even greater for Black people and African Americans, who experience both higher incidence and death rates than other populations.
Avery D. Posey, PhD, knows the statistic well–both as an African American scientist and a patient family member. Dr. Posey is the inaugural recipient of the Lustgarten Foundation Career Development Grant honoring Congressman John R. Lewis. He will discuss the importance of diversity within the field of pancreatic cancer research and the need for more BIPOCx participants in clinical trials. Made possible in part through the support of Bristol Myers Squibb, this Juneteenth webinar is part of the Lustgarten Foundation’s recognition of National Black Family Cancer Awareness Week June 17-23. Created by the U.S. Food & Drug Administration’s Oncology Center of Excellence, Black Family Cancer Week is designed to increase cancer awareness in one of the most vulnerable segments of the US population. #BlackFamCan This webinar is made possible in part through the support of Bristol Myers Squibb.

Learn More

In Person Walks
Are Back!

Join Hundreds of Walkers and Runners Across New York on June 27th  in the Critical Fight Against Pancreatic Cancer. The Lustgarten Foundation’s New York Walk Series is your chance to join forces with hundreds of others whose lives have been touched by pancreatic cancer. Together we will raise the critical funds and awareness needed to defeat this this devastating disease. Register. Donate. Fundraise. Walk where you want, when you want in your neighborhood. 100% of all donations fund lifesaving pancreatic cancer research. Whether you walk with us in New York City or walk in your own neighborhood, your action will change lives and inspire others! Choose an event near you and join our community of patients, survivors and loved ones coming together to celebrate, reflect and remember as we move closer to a cure for pancreatic cancer. Your Walk for Research will leave you energized and optimistic about the future. Together, we will defeat this disease!

Learn More

Lustgarten
Loot

The wait is over to get your LUSTGARTEN LOOT! Our first-ever online store is now LIVE. Shop all of our great Lustgarten merchandise, from tumblers to T-shirts to a cozy and versatile 4-in-1 blanket. We have something for everyone—even your four-legged friends! All proceeds fund pancreatic cancer research, so start shopping today!

Learn More

Give 5X the Hope
this Mother’s Day

In recognition of Mother’s Day, and in honor of Barbara, Stephanie and all women impacted by pancreatic cancer, please give your most generous gift todayNow through midnight on Mother’s Day—Sunday, May 9—your donation will be matched 5x up to $35,000*, thanks to Stephanie Kessler and Laura Hull, who also lost her mom to pancreatic cancer. That means every $1 becomes $5, and 100% of every donation funds life-saving pancreatic cancer research! Please give today!

Learn More

Career Development Awards Announced

The inaugural winners of the Lustgarten Foundation-AACR Career Development Awards for Pancreatic Cancer Research in Honor of Ruth Bader Ginsburg and John Robert Lewis were announced at the 2021 AACR annual meeting. For Dr. Avery Posey it was a bout with chickenpox when he was in 4th grade that spurred his interest in science. He was quarantined in one room for about a week and still remembers his grandmother lovingly applying calamine lotion to his blisters. “I was miserable, itchy, missed school, missed my friends, and all I kept thinking was there had to be a way to prevent this,” Posey says. A few years later, the chickenpox vaccine was unveiled and “most kids today don’t even know what chickenpox is,” he continues. “I thought for a while I wanted to be a doctor, but I realized in undergraduate school that real important changes in how we look at disease and treat disease is due to research.” Dr. Dannielle Engle thought she was going to be a violinist, a virtuoso maybe along the lines of Joshua Bell. She started college majoring in music, but switched gears and wound up majoring in biology. When she took a low-level job in a research lab while still an undergrad, it was the fruit fly and its simple genetic structure as well as the creativity shown by the investigators with whom she worked that made her realize science was her calling. “I was a pretty good violinist, not great,” she laughs. “But I got completely hooked on my work in the lab and I knew at that point my future was in research.”

Learn More

International Pancreatic Cancer Trial opens

 Researchers testing organoids use in predicting treatment outcomes

A new team of pioneering pancreatic cancer researchers has been formed to predict which treatments might work best for individual pancreatic cancer patients based on the molecular traits of tumors. The Pancreatic Cancer Convergence Dream Team is funded by the Pancreatic Cancer Collective, an initiative of the Lustgarten Foundation and Stand Up To Cancer® (SU2C), SU2C Canada and Pancreatic Cancer Canada. The team will be led by Jennifer Knox, MD, the Lewitt Chair in Pancreatic Cancer Research at the Princess Margaret Cancer Centre, part of University Health Network, and professor of medicine at the University of Toronto in Canada, and Elizabeth Jaffee, MD, a professor of oncology and deputy director of the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins in Baltimore, Maryland.

Learn More

Remembering Stephen Grand

Stephen Grand: Pancreatic Cancer Fighter and Research Funder

Our hearts are broken at the news of the passing of Lustgarten ally and donor, Stephen Grand of Belvedere, CA. A passionate and insightful philanthropist, as well as a pancreatic cancer patient, Steve was in the unique position of understanding the urgency of moving the research along quickly and the need to invest in the most innovative science with the greatest opportunity to drive real progress. Tomorrow is promised to no one, but Steve’s hope was that through his philanthropy pancreatic patients like himself would someday be promised more time.

Learn More

Register For Lustgarten Live!

Welcome to LustgartenLIVE! a new quarterly series of webinars designed to bring you face-to-face with the best researchers investigating pancreatic cancer. Moderated by Andrew Rakeman, PhD , Vice President of Research, each webinar in the series will focus on a different aspect of the research funded through your donations. REGISTRATION IS NOW OPEN for From the Lab to You: Clinical Advances
Clinical trials are designed to find more effective treatments than those currently available and provide a unique opportunity to better understand human disease. Clinical trials are especially important for pancreatic cancer patients, given the limited treatment options currently available. However, currently fewer than 5% of pancreatic cancer patients are enrolled in clinical trials. The Lustgarten Foundation is working to improve clinical trial participation by moving promising therapies into trials as quickly as possible, with the goal of having trials available for patients at every stage of the disease. During this webinar, two world-renowned pancreatic cancer researchers and clinicians, Dr. Elizabeth Jaffee of Johns Hopkins and Dr. Brian Wolpin of the Dana-Farber Cancer Institute, explain the Foundation’s critical role in moving research from the lab to the clinic, advancing clinical trials and better therapies. The Foundation established the Clinical Accelerator Initiative (CAI) to shorten the time from clinical trial concept to launch using a Lustgarten-developed process based on the best available science. These “smarter” clinical trials will examine cutting-edge biomarkers to observe key indicators of how the treatment is working and will generate large volumes of data scientists can use now and in the future.

Learn More

Generous
Donor Helps Bring Science to Clinic

Lustgarten Foundation receives $424,0000 grant establishing the Gail V. Coleman and Kenneth M. Bruntel Organoids for Personalized Therapy Project Devastated by the loss of her husband Kenneth Bruntel to pancreatic cancer, Gail Coleman is laser-focused on funding research offering hope and better treatment options for patients with metastatic cancer. Coleman knows the devastation of a pancreatic cancer diagnosis all too well, having also lost her 66-year-old mother followed by her 80-year-old father to the disease. Pancreatic cancer is considered a rare disease; that Coleman lost three of the people most precious to her to this cancer is wrenching. “I was very upset to learn there were still no good treatments for people with stage four pancreatic cancer when Ken was diagnosed,” Coleman said. “After Ken died, I spent a lot of time educating myself about pancreatic cancer research and decided to use Ken’s retirement fund to help advance this research. I concluded that translational research—which moves research from the laboratory to the clinic—offers the best chance for giving future patients some meaningful time after diagnosis. It also was important to me to invest in a project where our gift could make the most impact.”

Learn More

Meet Our New CEO

The Lustgarten Foundation today announced the appointment of Linda Tantawi as Chief Executive Officer. As CEO, Tantawi will expand the organization’s national presence to achieve its mission of finding a cure for pancreatic cancer. Since 1998, the Lustgarten Foundation has been at the forefront of advancements in understanding the disease and developing new and more effective treatments.

Announcing Tantawi’s appointment, Foundation Chairman Andrew Lustgarten said: “With the incredible vision of the Foundation’s previous leaders, we’ve made important strides—taking pancreatic cancer from an unsupported ‘orphan disease,’ to one that is now supported by a robust research program. Linda’s leadership skills and extensive experience in fundraising for national cancer nonprofits will help take the Foundation, and the research we support, to the next level.”

Learn More

Pancreatic Cancer News


Why Identical Genetic Mutations Cause Different Types of Cancer

19. 7. 21 ladmin
Why do alterations of certain genes cause cancer only in specific organs of the human body? Scientists at the German Cancer Consortium (DKTK), the Technical University of Munich (TUM), and the University Medical Center Göttingen have now demonstrated that cells originating from different organs are differentially susceptible to activating mutations in cancer drivers: The same […]

Matchmakers: How Basket Trials Match Patients With Drugs Based on Their Tumors

14. 7. 21 ladmin
Drew Huggins was running out of options. After his diagnosis of metastatic pancreatic cancer two years ago, at age 47, he hadn’t had any luck with the treatments he’d tried so far. His tumors didn’t respond to 13 cycles of FOLFIRINOX, an arduous four-drug chemotherapy combination. The chemo- therapy combination of gemcitabine and paclitaxel didn’t […]

Immune cells assemble – boosting the effects of chemotherapy in pancreatic cancer

9. 7. 21 ladmin
A new study from Queen Mary University of London has demonstrated that immune cells can be stimulated to assemble into special structures within pancreatic cancer such that, at least in a pre-clinical model, researchers can demonstrate an improvement in the efficacy of chemotherapy. The body’s immune system is a critical defence against illness such as […]

Annual Report to the Nation: Rapid Decrease in Lung Cancer and Melanoma Deaths Lead Overall Continued Decline in Cancer Death Rate

8. 7. 21 ladmin
Overall cancer death rates continue to decline in men and women for all racial and ethnic groups in the United States, according to the latest Annual Report to the Nation on the Status of Cancer. During 2001 to 2018, declines in lung cancer death rates accelerated, and death rates for melanoma declined considerably in more recent years, reflecting […]

MasSpec Pen shows promise in pancreatic cancer surgery

6. 7. 21 ladmin
A diagnostic tool called the MasSpec Pen has been tested for the first time in pancreatic cancer patients during surgery. The device is shown to accurately identify tissues and surgical margins directly in patients and differentiate healthy and cancerous tissue from banked pancreas samples. At about 15 seconds per analysis, the method is more than […]

Can mRNA Vaccines Fight Pancreatic Cancer? MSK Clinical Researchers Are Trying to Find Out

6. 7. 21 ladmin
Messenger RNA (mRNA) vaccines may be the hottest thing in science now as they help turn the tide against COVID-19. But even before the pandemic began, Memorial Sloan Kettering researchers had already been working to use mRNA vaccine technology to treat cancer. Vinod Balachandran a physician-scientist affiliated with the David M. Rubenstein Center for Pancreatic Cancer Research and […]

RWJBarnabas Health Pioneers Innovative Pancreatic Cyst Surveillance Program

5. 7. 21 ladmin
The incidental identification of pancreatic cysts has become more common with the increasing use of imaging modalities in clinical practice. Currently, an estimated 15% of Americans are believed to harbor a pancreatic cyst.1 Unlike other cysts within the body, pancreatic cysts are unique in that many pose an increased risk for development of pancreas cancer over […]

Blood test to spot pancreatic cancer: Pioneering check-up that can give early diagnosis of the disease could be available within months

5. 7. 21 ladmin
A test that spots pancreatic cancer from a single drop of blood could improve survival rates. The first blood test for early diagnosis of the hard-to-spot disease, it could be available within months. Pancreatic cancer has the lowest survival rate of the common cancers, with 7.3 per cent of patients alive five years after diagnosis, […]

Mouse Study Reveals New Therapeutic Target in Pancreatic Cancer

2. 7. 21 ladmin
The general five-year survival rate for people with pancreatic cancer is 10%. Survival rates and individual outcomes are based on many factors, including the specific stage of disease when it is diagnosed. Cancer cells can quickly become resistant to treatments through adaptation. Now, new research by scientists at Columbia University Vagelos College of Physicians and […]

Study identifies biomarker that could help to diagnose pancreatic cancer

29. 6. 21 ladmin
Researchers from Queen Mary University of London have identified a protein that could be used to aid in the diagnosis of pancreatic cancer. Findings from the new study suggest that a protein called pentraxin 3 (PTX3) may be a specific diagnostic biomarker – or biological measure – for pancreatic cancer, with the ability to differentiate […]

Get Involved Today

Get inspired and connect with patients, survivors and loved ones who are all on the same journey.

Back to Top